Wright Medical Group, Inc. (NASDAQ:WMGI), a global orthopaedic medical device company, today announced that pass-through reimbursement status has been granted by the Centers for Medicare & Medicaid Services for the Company’s GRAFTJACKET(R) Ulcer Repair Matrix and GRAFTJACKET(R) XPRESS Flowable Soft-Tissue Scaffold, two cutting-edge treatments for challenging wounds often associated with diabetes. The new “C” codes cover treatment of Medicare patients with a variety of problematic wounds in both hospital outpatient departments and wound care centers. Approximately 60% of diabetic foot wound sufferers rely on healthcare coverage through the Medicare program and most of the patients with moderate to severe wounds receive treatment for this condition in hospital outpatient departments or wound care centers.
